Sign In
CPSI Share                                                                      
​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​ ​​
Publication Type: Medication Safety Bulletin
Single or Multiple Incident: Multiple
Date: 11/1/2019 12:00:00 AM
Country: Hong Kong

This safety bulletin discusses the patient safety incidents that can occur with the use of valproate (valproic acid) in pregnancy. Indicated in the treatment of epilepsy and bipolar disorder, valproate ais associated with a significant risk of birth defects and developmental disorders in children born to women who take it during pregnancy. Risks include birth defects and development and learning problems. In response to the potential teratogenic effect for valproate in women of child bearing potential, 3 risk mitigation strategies were developed and are available in the recommendations section of this bulletin.

Additional Details

valproate (valproic acid)

Valproate - Risk minimisation measures in Hospital Authority